Targeted therapies with immunotherapies in kidney cancer

The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology. During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium.  The data from KETNOTE-426 potentially redefines the standard of care in […]

read more

Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the pembrolizumab (Keytruda) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval comes two months earlier than expected and is based on the results from the open-label KEYNOTE-426 study involving 861 patients. In this study, median progression-free […]

read more

Dalantercept plus axitinib combination for advanced kidney cancer

The results from a recent phase II study comparing a combination of dalantercept plus axitinib with axitinib plus placebo for second-line treatment of advanced renal cell carcinoma (RCC) were published in the journal Cancer this month. The study involved 124 patients with clear cell RCC who had been previously treated with an angiogenesis inhibitor, such […]

read more

Patients may not be able to tolerate recommended dose of cabozantinib

A recent study published on Oncology this month suggests that renal cell carcinoma (RCC) patients may not be able to tolerate the FDA-approved dose of cabozantinib, which was determined from the METEOR and CABOSUN clinical trials. In the current trial, a median daily dose of 33.2 mg was less than that administered in the METEOR […]

read more

First immunotherapy combination of ipilimumab plus nivolumab available to patients in England

We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund. The availability of […]

read more

HIF-2α inhibitor shows promise in patients with advanced kidney cancer

A recent phase I/II clinical trial with PT2977, a hypoxia-inducible factor (HIF)-2α inhibitor, has shown encouraging anti-tumour activity with a favourable safety profile in patients with previously-treated advanced renal cell carcinoma (RCC). Of the 55 patients who were treated with the HIF-2α inhibitor, 12 patients (22%) had a confirmed partial response. The study is still […]

read more

Bevacizumab plus erlotinib combination for advanced HLRCC

A recent study, published in Cancer Research and Treatment in March 2019, provides the first real-world evidence of the promising treatment of advanced hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic syndrome resulting from mutations in the gene that makes an enzyme called fumarate hydratase. Ten patients with advanced HLRCC-associated renal cell carcinoma […]

read more

Personalised in vitro model to help screen drugs for kidney cancer

Researchers at the University of Wisconsin Carbone Cancer Center in Madison, USA have developed an in vitro (outside the body) model that mimics a kidney tumour’s blood supply. The researchers used both normal and cancerous tissue from patients to grow three-dimensional blood vessels, and used them to test targeted drugs used to treat renal cell […]

read more

The hunt for a kidney cancer biomarker reveals two more potential candidates

As the hunt for a reliable biomarker for renal cell carcinoma (RCC) continues, two further studies this month reveal potential candidates. The first study, published in Targeted Oncology, describes serum (blood) α1-globulin as an independent predictor (prognostic factor) of overall survival and progression-free survival in metastatic RCC, and is correlated with a high amount of […]

read more

Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer

The results of a recent phase 2 study to evaluate the safety and efficacy of anlotinib for the first-line treatment of metastatic renal cell carcinoma (RCC) were published in The Oncologist this month. Anlotinib was developed in China, and is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in the growth of new blood […]

read more
Showing 1 to 10 of 494 results
  TOP